JP7886328B2 - 抗cd25抗体 - Google Patents
抗cd25抗体Info
- Publication number
- JP7886328B2 JP7886328B2 JP2023530329A JP2023530329A JP7886328B2 JP 7886328 B2 JP7886328 B2 JP 7886328B2 JP 2023530329 A JP2023530329 A JP 2023530329A JP 2023530329 A JP2023530329 A JP 2023530329A JP 7886328 B2 JP7886328 B2 JP 7886328B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- antigen
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306424.1 | 2020-11-20 | ||
| EP20306424 | 2020-11-20 | ||
| PCT/EP2021/082383 WO2022106665A1 (en) | 2020-11-20 | 2021-11-19 | Anti-cd25 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550446A JP2023550446A (ja) | 2023-12-01 |
| JP2023550446A5 JP2023550446A5 (cg-RX-API-DMAC7.html) | 2024-11-25 |
| JP7886328B2 true JP7886328B2 (ja) | 2026-07-07 |
Family
ID=73698744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530329A Active JP7886328B2 (ja) | 2020-11-20 | 2021-11-19 | 抗cd25抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240002522A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4247497A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7886328B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118108A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116917318A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124123A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021380966A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3199006A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022106665A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023222886A1 (en) | 2022-05-20 | 2023-11-23 | Depth Charge Ltd | Antibody-cytokine fusion proteins |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019175222A1 (en) | 2018-03-13 | 2019-09-19 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| JP2020514363A (ja) | 2017-03-17 | 2020-05-21 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のためのFc最適化抗CD25 |
| JP2020525517A (ja) | 2017-07-06 | 2020-08-27 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のための化合物及び方法 |
| WO2020234399A1 (en) | 2019-05-20 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US61816A (en) | 1867-02-05 | bunbab and a | ||
| US96973A (en) | 1869-11-16 | saxton | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| KR101703299B1 (ko) | 2007-06-01 | 2017-02-06 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| WO2013165972A2 (en) * | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
-
2021
- 2021-11-19 US US18/253,493 patent/US20240002522A1/en active Pending
- 2021-11-19 JP JP2023530329A patent/JP7886328B2/ja active Active
- 2021-11-19 CA CA3199006A patent/CA3199006A1/en active Pending
- 2021-11-19 AU AU2021380966A patent/AU2021380966A1/en not_active Abandoned
- 2021-11-19 KR KR1020237019908A patent/KR20230118108A/ko active Pending
- 2021-11-19 WO PCT/EP2021/082383 patent/WO2022106665A1/en not_active Ceased
- 2021-11-19 AR ARP210103224A patent/AR124123A1/es unknown
- 2021-11-19 CN CN202180090876.8A patent/CN116917318A/zh active Pending
- 2021-11-19 EP EP21807150.4A patent/EP4247497A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020514363A (ja) | 2017-03-17 | 2020-05-21 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のためのFc最適化抗CD25 |
| JP2020525517A (ja) | 2017-07-06 | 2020-08-27 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のための化合物及び方法 |
| WO2019175222A1 (en) | 2018-03-13 | 2019-09-19 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| WO2020234399A1 (en) | 2019-05-20 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023550446A (ja) | 2023-12-01 |
| EP4247497A1 (en) | 2023-09-27 |
| AR124123A1 (es) | 2023-02-15 |
| CN116917318A (zh) | 2023-10-20 |
| US20240002522A1 (en) | 2024-01-04 |
| KR20230118108A (ko) | 2023-08-10 |
| AU2021380966A1 (en) | 2023-06-22 |
| CA3199006A1 (en) | 2022-05-27 |
| WO2022106665A1 (en) | 2022-05-27 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260423 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260602 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260625 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7886328 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |